市場調査レポート
商品コード
1319145
幹細胞治療の世界市場-2023年~2030年Global Stem Cell Therapy Market - 2023-2030 |
● お客様のご希望に応じて、既存データの加工や未掲載情報(例:国別セグメント)の追加などの対応が可能です。 詳細はお問い合わせください。
幹細胞治療の世界市場-2023年~2030年 |
出版日: 2023年07月31日
発行: DataM Intelligence
ページ情報: 英文 195 Pages
納期: 即日から翌営業日
|
幹細胞治療の世界市場は、2022年に58億米ドルに達し、2030年には191億米ドルまで成長すると予測されています。世界の幹細胞治療市場は、予測期間中(2023-2030年)に16.6%のCAGRを示すと予測されています。幹細胞治療は、医療や研究の様々な分野で幅広い応用が期待されています。
幹細胞は、特殊な細胞に分化し、損傷した組織を再生する能力を持つユニークな細胞です。また幹細胞治療は、移植や修復のために機能する組織や臓器を実験室内で作製するプロセスである組織工学においても、重要な役割を果たしています。幹細胞は生体材料や成長因子と混合され、皮膚、軟骨、血管などの人工組織を形成し、損傷した組織や傷ついた組織の代わりとして利用されます。
臨床試験数の増加は、予測期間中に市場が成長するための重要な要因です。臨床研究の目的は、特定の疾患に対する幹細胞治療の有効性を評価することです。研究者は、その治療法の有効性や潜在的な利点を、望ましい結果を達成する能力を調査し、既存の治療法と比較することで分析することができます。
例えば、clinical trials.govによると、2020年4月1日、昆明医科大学延安附属病院は、糖尿病性腎症に対する臍帯間葉系幹細胞治療に関する臨床研究を開始しました。
神経変性疾患の有病率の上昇も、予測期間中に幹細胞治療市場が成長するための重要な 促進要因です。幹細胞治療は、幹細胞の再生特性により、神経変性疾患の治療アプローチとしての可能性を秘めています。
例えば、Parkinson's Foundationによると、神経変性疾患は世界中で何百万人もの人々に影響を及ぼしています。アルツハイマー病とパーキンソン病は、最も一般的な神経変性疾患です。米国では、620万人もの人々がアルツハイマー病を患っている可能性があり、100万人近くの米国人がパーキンソン病を患っています。
世界の幹細胞治療産業の成長を阻害している主な制約は、治療の選択肢に関する理解不足と胚性幹細胞に対する倫理的懸念です。例えば、国立生物工学情報センター(National Centre for Biotechnology Information)が提供した統計によると、未知の治療法に対する恐怖心や、代替治療法に関する一般市民の理解不足が最大の不安要因となっています。さらに、治療費が高いために導入が進まず、世界的に需要が減少しています。
COVID-19は幹細胞治療ビジネスに有益な影響を及ぼしました。パンデミックの最中、肺機能障害が死亡の主な原因であったからです。例えば、2020年1月、マイアミ大学の研究者は肺に障害を持つCOVID-19患者に2回の幹細胞注入を行っています。その結果、明らかな副作用は認められず、治療は成功しました。
ロシアとウクライナの紛争は、世界の幹細胞治療市場に中程度の影響を与えると推定されます。しかし、原材料の輸出入による影響は、予測期間中、世界の幹細胞治療市場の成長にほとんど影響を与えないと予想されます。
The global stem cell therapy market reached US$ 5.8 billion in 2022 and is expected to witness lucrative growth by reaching up to US$ 19.1 billion by 2030. The global stem cell therapy market is expected to exhibit a CAGR of 16.6% during the forecast period (2023-2030). Stem cell therapy has a wide range of applications in various fields of medicine and research.
Stem cells are unique cells that have the ability to differentiate into specialized cell types and regenerate damaged tissues . Also stem cell therapy plays a crucial role in tissue engineering; process of generating functioning tissues or organs in the laboratory for transplantation or repair. Stem cells are mixed with biomaterials and growth factors to form artificial tissues including skin, cartilage, and blood vessels that may be utilised to replace damaged or wounded tissues.
Rise in the number of clinical studies is the key driver that helps the market to grow during the forecast period. The objective of clinical trials is to assess the efficacy of stem cell therapy for specific medical conditions. Researchers can analyse the efficacy and potential advantages of a therapy by examining its capacity to accomplish desired results and comparing it to existing therapies .
For instance, according to clinical trials. gov, on April 1 2020, Yan'an Affiliated Hospital of Kunming Medical University started a clinical study on Umbilical Cord Mesenchymal Stem Cells Therapy for Diabetic Nephropathy which is currently in the early phase 1 where 15 participants have been enrolled for the studies and it is estimated to complete its study by Sep 2024.
Rise in the prevalence of neurodegenerative diseases is also a key driver that helps the stem cell therapy market to grow during the forecast period. Stem cell therapy holds potential as a treatment approach for neurodegenerative diseases due to the regenerative properties of stem cells.
For instance, according to the Parkinson's Foundation Neurodegenerative diseases affect millions of people worldwide. Alzheimer's disease and Parkinson's disease are the most common neurodegenerative diseases. In the United States, as many as 6.2 million people may have Alzheimer's disease and Nearly a million Americans are living with Parkinson's disease.
The main constraints impeding the growth of the global stem cell therapy industry are a lack of understanding about treatment choices and ethical concerns about embryonic stem cells. For instance, according to statistics provided by the National Centre for Biotechnology Information, the biggest source of worry is the fear of unknown treatments and a lack of public understanding about treatment alternatives. Furthermore, the high cost of the treatments leads to lesser adoption, resulting in decreasing demand for the product globally.
COVID-19 has had a beneficial impact on the stem cell treatment business, as lung dysfunction was the leading cause of mortality during the pandemic. For instance, in January 2020, University of Miami researchers provided two stem cell infusions to COVID-19 patients with lung damage. The results revealed no discernible adverse effects, and the treatment was successful.
The Russia-Ukraine conflict is estimated to have a moderate impact on the global stem cell therapy market, owing to the low prevalence and absence of key market players in this region. However, the impact of the import and export of raw materials is expected to have little influence over the global stem cell therapy market growth over the forecast period.
The global stem cell therapy market is segmented based on type, cell source, therapeutic application, end user and region.
The musculoskeletal disorders from the therapeutic application segment with around 41.3% are expected to dominate during the forecast period, owing to the prevalence of muscular disease, and the increase in R&D musculoskeletal disorders, which are a large category of illnesses that affect the muscles, bones, joints, tendons, ligaments, and other elements of the musculoskeletal system. These illnesses can cause discomfort, stiffness, reduced range of motion, and other symptoms that interfere with everyday activities.
For instance, in Jan 2023,The National Ethics Committee has approved RegenOrthosport, a BMAC-PRP combination treatment for patients with Musculoskeletal Disorders, using Autologous Bone Marrow Aspirate Concentrate and Platelet-Rich Plasma.
North America is estimated to hold about 40.6% of the total market share throughout the forecast period due to the presence of key players engaged in developing stem cell therapies, advanced healthcare infrastructure, extensive R&D, supportive reforms from the healthcare sector, and strong reimbursement policies.
For instance, in June 2023, StemCyte has signed a cooperation agreement with a US immune cell therapy company to supply raw materials for allogeneic-modified cell therapy. The company is developing allogeneic genetically modified CAR-NK cells using umbilical cord blood. StemCyte will supply the necessary cellular raw materials for worldwide allogeneic cell therapy product development.
The major global players in the stem cell therapy include: Advanced Cell Technology Inc, Angel Biotechnology, Bioheart Inc, Brainstorm Cell Therapeutics, Caladrius Biosciences, Celgene Corporation, Cellartis AB, CellGenix GmbH, Cellular Engineering Technologies Inc, Gamida Cell and others.
The global stem cell therapy market report would provide approximately 53 tables, 54 figures and 195 Pages.
LIST NOT EXHAUSTIVE